Opinion|Videos|January 30, 2025
Oral vs IV Iron in Clinical Practice
Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including gastrointestinal adverse effects and poor absorption, leading many patients to experience iron intolerance or inadequate response, which often necessitates switching to intravenous iron administration for more reliable and rapid repletion of iron stores.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the advantages and disadvantages of oral versus intravenous (IV) iron therapy in the treatment of IDA?
- Please define oral iron intolerance. What are the potential reasons and subsequent steps for patients with IDA who have had an unsatisfactory response to oral iron therapy?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5